


**For more information about the nefIgArd study, please contact:**

Nef-301 | 28-DEC-2018 | Version 3

**Have you been diagnosed with IgA nephropathy?**

If so, consider joining the nefIgArd clinical research study.



**calliditas**  
THERAPEUTICS

**nefIgArd**



## What is the nefIgArd study?

The nefIgArd clinical research study is for patients diagnosed with primary IgA Nephropathy (IgAN), who are at risk of developing end-stage kidney disease even though they are taking medication to preserve kidney function.

IgAN, also known as Berger's disease, is a kidney disease where the antibody called immunoglobulin A (IgA) embeds itself into the kidneys. This causes inflammation, which can affect the kidney's ability to filter the blood. Some cases of IgAN progress slowly without symptoms or go into remission, while others lead to end-stage kidney failure. Currently, there are no drugs approved specifically to treat IgAN.

The purpose of the nefIgArd study is to look at the safety, tolerability, and effectiveness of the study drug Nefecon compared to placebo (no active ingredients) in patients with IgAN, who are at risk of progressing to end-stage kidney disease.



## Who can participate in the study?

You may be able to participate in this study if you meet these criteria\*:

- 18 years of age or older
- Diagnosed with IgAN and have had the diagnosis confirmed by a kidney tissue sample
- On a stable dose of medication to preserve kidney function (e.g., irbesartan, losartan, ramipril, captopril) for at least 3 months before starting the study

\*Other criteria will also apply.

## What is the study drug?

The study drug (Nefecon) is an investigational drug (capsule) taken by mouth. It is the first drug designed with the potential to treat the cause of IgAN and reduce kidney inflammation instead of merely treat IgAN symptoms.

Nefecon is considered "investigational" because it is still being studied and can only be used in research.

## What can study participants expect?

If you decide to join the study, there will be 2 parts: a treatment period of approximately 9 months and long-term follow-up period that may last up to about 5 years. In total, your participation in the study may last between about 3 years and up to 6 years, depending on when you start in the study. You can expect the following:

### Treatment Period

*Lasting approximately 9 months*

- Be randomly selected (like the flip of a coin) with a 50 percent chance to receive either the study drug or placebo. Placebo looks like the study drug, but does not have any active ingredients
- Take 4 capsules once per day of study drug (or placebo) for 9 months

### Long-term Follow-Up Period

- No longer take the study drug
- Continue on your prescribed medication that preserves kidney function
- Attend visits at the study site every 6 months and be contacted by telephone every 3 months

Your health will be monitored throughout the study by a study team experienced in your disease and clinical trials.

Nefecon might help slow down the progress of the disease, IgAN, but there is no guarantee that the study treatment will help you. The information that is collected from this study may help researchers find new treatments for future patients.

Your participation in this study is voluntary, and you may choose to discontinue study participation at any time.